9,865 results match your criteria Imaging in Non-Small Cell Lung Cancer

Feasibility and clinical utility of a workflow interfacing radiation oncology lung stereotactic body radiotherapy treatment planning and diagnostic radiology.

Pract Radiat Oncol 2022 Jun 22. Epub 2022 Jun 22.

Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah. Electronic address:

Stereotactic body radiotherapy (SBRT) is commonly used to treat early stage non-small cell lung cancer (NSCLC). SBRT beam arrangements include multiple entry/exit pathways resulting in irregular low dose distributions within normal lung parenchyma. An improved understanding of post-treatment radiographic changes may improve the ability to predict clinical complications including radiation pneumonitis as well as assist in early detection of local failures. Read More

View Article and Full-Text PDF

Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.

J Cancer Res Clin Oncol 2022 Jun 24. Epub 2022 Jun 24.

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Via Giuseppe Massarenti, 9, 40138, Bologna, Italy.

Purpose: The presence of bone metastasis at baseline has been associated with dismal prognosis under immunotherapy in advanced non-small cell lung cancer (NSCLC). Response Evaluation Criteria in Solid Tumors (RECIST) criteria may be limited for bone-specific response evaluation. Whether their assessment through MD Anderson (MDA) criteria predict immunotherapy efficacy is unknown. Read More

View Article and Full-Text PDF

Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event.

Mol Clin Oncol 2022 Jul 1;17(1):120. Epub 2022 Jun 1.

Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan.

Aseptic meningitis is a rare immune-related adverse event (irAE), which occurs during treatment with immune checkpoint inhibitors (ICIs). This condition has non-specific symptoms and exhibits no clear signs on magnetic resonance imaging (MRI). There are only a few reports of aseptic meningitis caused by pembrolizumab treatment for non-small cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF

Management of Combined Therapy (Ceritinib, , , and Photobiomodulation) in Advanced Non-Small-Cell Lung Cancer: A Case Report.

Life (Basel) 2022 Jun 9;12(6). Epub 2022 Jun 9.

Department of Biomedical Engineering, Ming Chuan University, Taoyuan 33348, Taiwan.

The 5-year survival rate of non-small-cell lung cancer (NSCLC) is still low (<21%) despite recent improvements. Since conventional therapies have a lot of side effects, combined therapy is strongly recommended. Here, we report a patient with advanced NSCLC who received combined therapy, including ceritinib, photobiomodulation (PBM), ACGL ( (), and ()). Read More

View Article and Full-Text PDF

A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer.

Front Cardiovasc Med 2022 6;9:878211. Epub 2022 Jun 6.

Pulmonary Department, Centre Hospitalier Universitaire (CHU) Haut-Lévèque, Bordeaux, France.

Background: Immune checkpoint inhibitors (ICIs) are widely used in lung cancer management. However, myocarditis, which is a rare, yet potentially severe adverse-related event associated with ICIs, could be under-reported.

Objectives: This study is aimed to prospectively evaluate the cumulative incidence rate of myocarditis, through systematic screening, among patients receiving ICIs for lung cancer. Read More

View Article and Full-Text PDF

Leptomeningeal Metastatic L858R -mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib.

Onco Targets Ther 2022 14;15:659-667. Epub 2022 Jun 14.

Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Leptomeningeal carcinomatosis (LMC) is a known sequel of metastatic lung cancer and its treatment is challenging. Nevertheless, treatment options for LMC due to metastatic epidermal growth factor receptor-mutant (-mutant) lung adenocarcinoma are expanding. We present a 52-year-old male patient with metastatic non-small-cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.

Eur J Cancer 2022 Jun 19;171:203-231. Epub 2022 Jun 19.

Universite' de Paris, INSERM U976, AP-HP, Dermatology Department, Saint Louis Hospital, Paris, France. Electronic address:

Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all cutaneous malignancies. It is found predominantly in white populations and risk factors include advanced age, ultraviolet exposure, male sex, immunosuppression, such as AIDS/HIV infection, haematological malignancies or solid organ transplantation, and Merkel cell polyomavirus infection. MCC is an aggressive tumour with 26% of cases presenting lymph node involvement at diagnosis and 8% with distant metastases. Read More

View Article and Full-Text PDF

Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC.

Technol Cancer Res Treat 2022 Jan-Dec;21:15330338221107966

Department of Radiation Oncology, 92323Zhongshan Hospital, Fudan University, Shanghai, China.

To access the comparative dosimetric and radiobiological advantages of two methods of intensity-modulated radiation therapy (IMRT)-based hybrid radiotherapy planning for stage III nonsmall cell lung cancer (NSCLC). Two hybrid planning methods were respectively characterized by conventional fraction radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT) and CFRT and simultaneous integrated boost (SIB) planning. All plans were retrospectively completed using the 2 methods for 20 patients with stage III NSCLC. Read More

View Article and Full-Text PDF

Editorial for "Computed DWI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer than that of Actual DWI, STIR Imaging and FDG-PET/CT".

J Magn Reson Imaging 2022 Jun 22. Epub 2022 Jun 22.

Institute for Diagnostic and Interventional Radiology, University Hospital Cologne, Kerpener Straße 62, Cologne, 50937, Germany.

View Article and Full-Text PDF

Rapid On-site Evaluation and Final Cytologic Diagnoses Correlation During Endobronchial Ultrasonography.

J Bronchology Interv Pulmonol 2022 Jul 9;29(3):191-197. Epub 2021 Sep 9.

Departments of Pulmonology.

Background: The cost-effectiveness and low rate of inadequate sampling with the use of rapid on-site evaluation (ROSE) along with endobronchial ultrasonography (EBUS) is well established. Our aim in this study was to evaluate the correlation of ROSE during EBUS and final cytologic diagnosis and also to see if ROSE might predict the subtype of lung cancer.

Patients And Methods: All consecutive subjects who attended our clinic between January 2016 and January 2019 for the evaluation of pathologic mediastinal and/or hilar lymph nodes (LNs)/mass using EBUS were enrolled into our prospective study. Read More

View Article and Full-Text PDF

Clinical quality indicators of pathways to oncological lung surgery.

N Z Med J 2022 Jun 10;135(1556):11-22. Epub 2022 Jun 10.

Cardiothoracic Surgery Registrar, Department of Cardiothoracic Surgery, Dunedin Public Hospital, Dunedin, Otago.

Aims: Multidisciplinary team (MDT) meetings are a standard of care for lung cancer management in many regions around the world. Clinical quality indicators (CQIs) can be used to assess the proficiency of these multidisciplinary teams and compare their performance against those recommended by local and international guidelines. The effectiveness of the lung cancer MDT meeting at Dunedin Public Hospital has been evaluated using CQIs with a focus on the timeliness of surgical management. Read More

View Article and Full-Text PDF

Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers.

Clin Cancer Res 2022 Jun 21. Epub 2022 Jun 21.

Case Western Reserve University, Cleveland, OH, United States.

Purpose: Tumor-associated vasculature is distinguished its convolutedness, leakiness, and chaotic architecture, which facilitates the creation of a treatment resistant tumor microenvironment. Measurable differences in these attributes might help stratify patients by potential benefit of systemic therapy. In this work, we present a new category of radiomic quantitative tumor-associated vasculature (QuanTAV) biomarkers and investigate their ability to predict outcomes across multiple cancers, imaging modalities, and treatment regimens. Read More

View Article and Full-Text PDF

Use of Preoperative FDG PET/CT and Survival of Patients with Resectable Non-Small Cell Lung Cancer.

Radiology 2022 Jun 21:212798. Epub 2022 Jun 21.

From the Graduate Institute of Business Administration, College of Management (W.M.C., M.C., J.G.H., T.S.L., B.C.S., S.Y.W.), and Artificial Intelligence Development Center (B.C.S., S.Y.W.), Fu Jen Catholic University, Taipei, Taiwan; Big Data Center (W.M.C., S.Y.W.), Division of Radiation Oncology (S.Y.W.), and Cancer Center (S.Y.W.), Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, No. 111, Section 3, Hsing-Long Rd, Taipei 116, Taiwan; Department of Food Nutrition and Health Biotechnology (S.Y.W.) and Department of Healthcare Administration (S.Y.W.), College of Medical and Health Science, Asia University, Taichung, Taiwan; Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan (S.Y.W.); and Department of Management, College of Management, Fo Guang University, Yilan, Taiwan (S.Y.W.).

Background The added value of preoperative PET/CT for the overall survival of patients with resectable non-small cell lung cancer (NSCLC) is unknown. Purpose To investigate the association of the use of preoperative PET/CT on survival of patients with resectable stage I-IIIB NSCLC. Materials and Methods In this retrospective study, patients with resectable stage I-IIIB NSCLC who underwent thoracic surgery from January 1, 2009, to December 31, 2018, from the Taiwan Cancer Registry were included. Read More

View Article and Full-Text PDF

Construction and validation of a nomogram based on N6-Methylandenosine-related lncRNAs for predicting the prognosis of non-small cell lung cancer patients.

Cancer Med 2022 Jun 21. Epub 2022 Jun 21.

Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Background: The N6-methyladenosine (m A) can modify long non-coding RNAs (lncRNAs), thereby influencing a wide array of biological functions. However, the prognosis of m A-related lncRNAs (m ARLncRNAs) in non-small cell lung cancer (NSCLC) remains largely unknown.

Methods: Pearson correlation analysis was used to identify m ARLncRNAs in 1835 NSCLC patients and with the condition (|Pearson R| > 0. Read More

View Article and Full-Text PDF

Circular RNA EPB41 expression predicts unfavorable prognoses in NSCLC by regulating miR-486-3p/eIF5A axis-mediated stemness.

Cancer Cell Int 2022 Jun 20;22(1):219. Epub 2022 Jun 20.

Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, 279 Zhouzhu Road, Pudong New Area, Shanghai, 201318, People's Republic of China.

Dysregulation of circular RNAs (circRNAs) has recently been found to play an important role in the progression and development of cancers such as non-small cell lung cancer (NSCLC). Yet the functions of many circRNAs in NSCLC remain unclear. In this study, the circRNA expression profiles in NSCLC tumor tissues and adjacent non-tumorous tissues were detected by high-throughput sequencing. Read More

View Article and Full-Text PDF

Access to Care Metrics in Stage I Lung Cancer: Improved Access Is Associated with Improved Survival.

Ann Thorac Surg 2022 Jun 17. Epub 2022 Jun 17.

Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO; VA St. Louis Health Care System, St. Louis, MO.

Background: Equitable access to care is a critical component of comprehensive surgical lung cancer management. Despite this, quality measures (QMs) assessing pre-operative access to care are lacking. We determined several pre-operative QMs based on contemporary treatment guidelines and hypothesized that poor access to care was associated with worse outcomes. Read More

View Article and Full-Text PDF

Synthesis of a versatile mitochondria-targeting small molecule for cancer near-infrared fluorescent imaging and radio/photodynamic/photothermal synergistic therapies.

Mater Today Bio 2022 Jun 7;15:100316. Epub 2022 Jun 7.

School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, China.

Although as a mainstay modal for cancer treatment, the clinical effect of radiotherapy (RT) does not yet meet the need of cancer patients. Developing tumour-preferential radiosensitizers or combining RT with other treatments has been acknowledged highly necessary to enhance the efficacy of RT. The present study reported a multifunctional bioactive small-molecule (designated as IR-83) simultaneously exhibiting tumour-preferential accumulation, near-infrared imaging and radio/photodynamic/photothermal therapeutic effects. Read More

View Article and Full-Text PDF

[F]FDG-PET/CT radiomics and artificial intelligence in lung cancer: Technical aspects and potential clinical applications.

Semin Nucl Med 2022 Jun 15. Epub 2022 Jun 15.

Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria. Electronic address:

Lung cancer is the second most common cancer and the leading cause of cancer-related death worldwide. Molecular imaging using [F]fluorodeoxyglucose Positron Emission Tomography and/or Computed Tomography ([F]FDG-PET/CT) plays an essential role in the diagnosis, evaluation of response to treatment, and prediction of outcomes. The images are evaluated using qualitative and conventional quantitative indices. Read More

View Article and Full-Text PDF

Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab.

Lung Cancer 2022 Jun 13;170:58-64. Epub 2022 Jun 13.

Departments of Radiation Oncology and Biostatistics & Information, Mayo Clinic, 200 1st St SW, Rochester, MN, USA. Electronic address:

Objectives: The incidence and predictors of pneumonitis for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) in the era of consolidation durvalumab have yet to be fully elucidated. In this large single institution analysis, we report the incidence of and factors associated with grade 2 + pneumonitis in NSCLC patients treated with the PACIFIC regimen.

Materials And Methods: We identified all patients treated at our institution with definitive CRT followed by durvalumab from 2018 to 2021. Read More

View Article and Full-Text PDF

A multi-classification model for non-small cell lung cancer subtypes based on independent subtask learning.

Med Phys 2022 Jun 17. Epub 2022 Jun 17.

Beijing Advanced Innovation Center for Biomedical Engineering, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100191, China.

Purpose: The non-small cell lung cancer (NSCLC) can be divided into adenocarcinoma (ADC), squamous cell carcinoma (SCC), large cell carcinoma (LCC) and not otherwise specified (NOS), which is crucial for clinical decision-making. However, current related researches are rare for the complex multi-classification of NSCLC, mainly due to the serious data imbalance, the difficulty to unify the feature space and the complicated decision boundary among multiple subtypes. The machine learning method of traditional "one-vs-one" (OVO) is difficult to solve these problems and achieve good results. Read More

View Article and Full-Text PDF

Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer.

Insights Imaging 2022 Jun 17;13(1):103. Epub 2022 Jun 17.

Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Korea.

Objectives: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly. Read More

View Article and Full-Text PDF

Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease.

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-15

Division of Cancer Medicine, Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Given the success of immunotherapy in treating patients with metastatic disease in a variety of tumor types, there is tremendous enthusiasm for expanding the use of immunotherapy to those with early-stage cancer. Administering immunotherapy in the neoadjuvant, preoperative setting is a biologically sound approach because preclinical studies have shown that stronger and broader immune responses can be generated if immunotherapy is administered while the tumor and/or draining lymph nodes are intact. It is therefore likely that administering immunotherapy preoperatively will generate optimal immune responses, leading to high rates of pathologic response as well as improved long-term survival. Read More

View Article and Full-Text PDF

Surgical resection, radiotherapy and percutaneous thermal ablation for treatment of stage 1 non-small cell lung cancer: protocol for a systematic review and network meta-analysis.

BMJ Open 2022 Jun 16;12(6):e057638. Epub 2022 Jun 16.

Division of Vascular and Interventional Radiology, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA

Introduction: Non-small cell lung cancer (NSCLC) makes up the majority of lung cancer cases. Currently, surgical resection is the gold standard of treatment. However, as patients are becoming medically more complex presenting with advanced disease, minimally invasive image-guided percutaneous ablations are gaining popularity. Read More

View Article and Full-Text PDF

Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.

Bioengineered 2022 05;13(5):13906-13918

Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

The active ingredient of the traditional Chinese medicine comfrey is shikonin, a naphthoquinone compound. The focus of this study was to investigate the effect of shikonin on the proliferation, invasion, migration, and chemoresistance of non-small cell lung cancer (NSCLC) cells, and to explore its underlying molecular biological mechanisms. The results show that shikonin inhibited the viability, proliferation, invasion, and migration of NSCLC cells A549 and PC9, and induced apoptosis. Read More

View Article and Full-Text PDF

Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer.

Acta Pharmacol Sin 2022 Jun 15. Epub 2022 Jun 15.

State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

The combination of vascular endothelial growth factor (VEGF) inhibitors and tyrosine kinase inhibitors (TKIs) is newly available for molecular targeted therapy against non-small cell lung cancer (NSCLC) in clinic. However, the therapeutic benefits remain unsatisfying due to the poor drug delivery to targets of interest. In this study, we developed bevacizumab-coated gefitinib-loaded nanoparticles (BCGN) with dual-responsive drug release for inhibiting tumor angiogenesis and phosphorylation of epidermal growth factor receptor (EGFR). Read More

View Article and Full-Text PDF

Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy.

Sci Rep 2022 Jun 15;12(1):9993. Epub 2022 Jun 15.

Department of Radiology, Center for Biomedical Image Computing and Analytics (CBICA), University of Pennsylvania, Rm D702 Richards Bldg., 3700 Hamilton Walk, Philadelphia, PA, 19104, USA.

We aim to determine the feasibility of a novel radiomic biomarker that can integrate with other established clinical prognostic factors to predict progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) undergoing first-line immunotherapy. Our study includes 107 patients with stage 4 NSCLC treated with pembrolizumab-based therapy (monotherapy: 30%, combination chemotherapy: 70%). The ITK-SNAP software was used for 3D tumor volume segmentation from pre-therapy CT scans. Read More

View Article and Full-Text PDF

SPF: A spatial and functional data analytic approach to cell imaging data.

PLoS Comput Biol 2022 Jun 15;18(6):e1009486. Epub 2022 Jun 15.

Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America.

The tumor microenvironment (TME), which characterizes the tumor and its surroundings, plays a critical role in understanding cancer development and progression. Recent advances in imaging techniques enable researchers to study spatial structure of the TME at a single-cell level. Investigating spatial patterns and interactions of cell subtypes within the TME provides useful insights into how cells with different biological purposes behave, which may consequentially impact a subject's clinical outcomes. Read More

View Article and Full-Text PDF

Automated detection and segmentation of non-small cell lung cancer computed tomography images.

Nat Commun 2022 Jun 14;13(1):3423. Epub 2022 Jun 14.

The D-Lab, Department of Precision Medicine, GROW- School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.

Detection and segmentation of abnormalities on medical images is highly important for patient management including diagnosis, radiotherapy, response evaluation, as well as for quantitative image research. We present a fully automated pipeline for the detection and volumetric segmentation of non-small cell lung cancer (NSCLC) developed and validated on 1328 thoracic CT scans from 8 institutions. Along with quantitative performance detailed by image slice thickness, tumor size, image interpretation difficulty, and tumor location, we report an in-silico prospective clinical trial, where we show that the proposed method is faster and more reproducible compared to the experts. Read More

View Article and Full-Text PDF

Potential advantages of FDG-PET radiomic feature map for target volume delineation in lung cancer radiotherapy.

J Appl Clin Med Phys 2022 Jun 14:e13696. Epub 2022 Jun 14.

Department of Medical Physics, Tehran University of Medical Sciences, Tehran, Iran.

Purpose: To investigate the potential benefits of FDG PET radiomic feature maps (RFMs) for target delineation in non-small cell lung cancer (NSCLC) radiotherapy.

Methods: Thirty-two NSCLC patients undergoing FDG PET/CT imaging were included. For each patient, nine grey-level co-occurrence matrix (GLCM) RFMs were generated. Read More

View Article and Full-Text PDF